Table 5. Clinical and demographic data for ordinary-luminal quantiles Q1, Q2, Q3 and Q4.
| METABRIC training | METABRIC validation | ROCK | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | Q1 | Q2 | Q3 | Q4 | p -value | Q1 | Q2 | Q3 | Q4 | p -value | Q1 | Q2 | Q3 | Q4 | p -value |
| Size [mm] | 23.1 | 23.2 | 28.7 | 27 | 6.3 ⋅ 10−6 | 21.3 | 24.5 | 25.7 | 27.8 | 6.6 ⋅ 10−6 | 20.1 (220) | 20.4 (204) | 21.8 (201) | 22.6 (183) | 0.02 |
| Grade | 1.9 | 2.1 | 2.4 | 2.6 | 1.2 ⋅ 10−22 | 1.8 | 2.2 | 2.3 | 2.7 | 2.5 ⋅ 10−24 | 1.8 (147) | 2.1 (113) | 2.3 (114) | 2.6 (108) | 5.3 ⋅ 10−20 |
| NPI | 3.3 | 3.7 | 4.1 | 4.2 | 4.7 ⋅ 10−15 | 3.2 | 3.7 | 3.9 | 4.3 | 5.1 ⋅ 10−18 | N/A | N/A | N/A | N/A | N/A |
| Age at diagnosis [y.] | 63.1 | 63.2 | 63.6 | 64.3 | 0.92 | 61.2 | 64.5 | 64.4 | 64 | 0.74 | 54.6 (171) | 56.2 (195) | 56.6 (204) | 56.1 (202) | 0.52 |
| Lymph nodes positive | 1.1 | 1.4 | 2 | 2.2 | 0.053 | 1.1 | 1.2 | 1.8 | 2.2 | 0.12 | N/A | N/A | N/A | N/A | N/A |
| PR+/all [%] | 76% | 76% | 66% | 60% | 0.0029 | 78% | 84% | 65% | 67% | 1.1 ⋅ 10−4 | 86% (85) | 88% (96) | 84% (81) | 68% (117) | 0.0011 |
| Lum A/all [%] | 100% | 94% | 66% | 15% | 2.7 ⋅ 10−71 | 100% | 94% | 60% | 7% | 3.2 ⋅ 10−80 | 100% | 90% | 60% | 10% | 2.2 ⋅ 10−113 |
| P53 mutated/all [%] | 4% (72) | 3% (64) | 9% (75) | 11% (64) | 0.21 | 2% (54) | 4% (89) | 3% (72) | 12% (65) | 0.035 | N/A | N/A | N/A | N/A | N/A |
| 10-year survival rate | 0.92 (148) | 0.81 (147) | 0.72 (146) | 0.62 (147) | 2.1 ⋅ 10−6 | 0.87 (138) | 0.79 (167) | 0.67 (140) | 0.58 (136) | 5.7 ⋅ 10−9 | 0.83 (214) | 0.81 (195) | 0.63 (186) | 0.49 (168) | 3.7 ⋅ 10−18 |
| Lower limit | 0.87 | 0.74 | 0.64 | 0.54 | 0.81 | 0.71 | 0.59 | 0.5 | 0.76 | 0.75 | 0.56 | 0.41 | |||
| Upper limit | 0.98 | 0.89 | 0.8 | 0.72 | 0.95 | 0.87 | 0.77 | 0.69 | 0.9 | 0.88 | 0.72 | 0.58 | |||
| Population | 158 | 157 | 157 | 157 | 147 | 183 | 155 | 144 | 244 | 244 | 244 | 243 | |||
The mean values of tumour size, grade, NPI, the average numbers of positive lymph nodes, and patients’ mean age for the ordinary-luminal quantiles Q1, Q2, Q3 and Q4 are listed in this table. The ratios of IHC PR- and HER2-positively measured cases, the prevalence of a p53 mutation, and the constitution of luminal A labels within each group, are provided as percentages. P-values indicating the significance of the difference between the results are also provided for each data set, where the multidimensional Kruskal-Wallis test (one-way ANOVA on ranks) was applied to numeric parameters and the Proportion test—to Boolean given as percentages. The survival rates correspond to prognostic probabilities, where 1 is the perfect prediction and 0 stands for a certain death; the lower and upper limits correspond to the 95% confidence interval of each Kaplan-Meier curve; the overall Log-rank test p-values of survival curves stratification are listed for each data set. In the METABRIC data set the disease-specific survival information was considered, while in the ROCK data set it corresponds to relapse-free survival. The number of samples in each subgroup is denoted in the last row. Where the number of samples available for calculation of each characteristic was lower than 95% of the population, it is provided in parenthesis. “N/A” stands for “non-applicable” due to missing data.